Corecentryx

Corecentryx is a biotechnology company focused on the discovery and validation of novel therapeutic targets, particularly those located on the cell surface. The company employs a proprietary platform to identify 'dark matter' within the human proteome—proteins that are potentially druggable but have been overlooked by traditional discovery methods. Founded by Dr. Michael Kinch, a prominent figure in oncology and drug development, Corecentryx aims to address significant unmet needs in cancer and infectious diseases. By integrating deep biological insights with advanced screening technologies, the company seeks to streamline the transition from target identification to clinical development. Corecentryx operates primarily in the pre-clinical stage, building a pipeline of candidates while exploring collaborative opportunities with industry partners.